Expand OTLK Menu
OTLK MENU

OTLK Latest Press Releases

-- August 14, 2026 --

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA Globe Newswire 7:15 AM

-- August 12, 2026 --

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants Globe Newswire 9:45 PM
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants Globe Newswire 4:01 PM

-- August 6, 2026 --

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 Globe Newswire 8:45 AM

-- July 24, 2026 --

Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD Globe Newswire 2:40 PM

-- June 16, 2026 --

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a Treatment for Wet AMD Globe Newswire 8:02 AM

-- June 1, 2026 --

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) Globe Newswire 8:46 AM

-- May 28, 2026 --

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Globe Newswire 4:00 PM

-- May 26, 2026 --

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA (bevacizumab-vikg) Globe Newswire 7:00 AM

-- May 15, 2026 --

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- April 23, 2026 --

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering Globe Newswire 4:05 PM

-- April 22, 2026 --

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Globe Newswire 8:30 AM

-- April 21, 2026 --

Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) Globe Newswire 9:05 AM

-- April 7, 2026 --

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA Globe Newswire 8:50 AM

-- March 25, 2026 --

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering Globe Newswire 4:05 PM

-- March 24, 2026 --

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering Globe Newswire 7:00 AM

-- March 23, 2026 --

Outlook Therapeutics Announces Proposed Public Offering Globe Newswire 5:30 PM
Market Data Delayed 15 Minutes